Actively Recruiting

Phase 2
Age: 2Years - 11Years
All Genders
NCT02616302

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Led by Takeda · Updated on 2026-01-14

70

Participants Needed

33

Research Sites

244 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of GERD include pain in the stomach or throat, difficulty eating, and throwing up. Symptomatic nonerosive GERD is a condition where people have the symptoms of GERD but the esophagus has not been damaged. People of all ages can have GERD. The causes of GERD in children are similar to those in adults and teenagers. Dexlansoprazole is a medicine that has been shown to help relieve the symptoms of GERD in adults and teenagers. This study aims to find out if dexlansoprazole doses given to children with symptomatic nonerosive GERD, based on their body weight, helps them feel better.

CONDITIONS

Official Title

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Who Can Participate

Age: 2Years - 11Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant and parent/legal guardian can understand and follow study requirements
  • Signed informed consent by parent/legal guardian and assent by participant if appropriate
  • History of GERD symptoms for at least 3 months before screening
  • Meets electronic diary criteria of heartburn symptoms on at least 3 of 7 consecutive days during screening
  • No evidence of erosive esophagitis by Los Angeles Classification
  • Age between 2 and 11 years inclusive at screening
Not Eligible

You will not qualify if you...

  • Cardiovascular, pulmonary, nervous system, liver, blood, kidney, or metabolic disorders, severe allergy, asthma, or significant skin rash that may affect participation
  • Diseases affecting the esophagus like varices, scleroderma, infections, strictures, or history of esophageal radiation or trauma
  • Medical history or tests indicating diseases that may interfere with the study
  • Allergies to dexlansoprazole, proton pump inhibitors, or antacids
  • Use or anticipated need for disallowed medications during the study
  • Conditions requiring inpatient surgery during the study
  • History of Barrett's esophagus with dysplasia
  • Known or suspected eosinophilic esophagitis
  • History of celiac disease or positive tissue transglutaminase antibody test
  • History of inflammatory bowel disease or irritable bowel syndrome
  • Active gastric or duodenal ulcers within 4 weeks before Day -1
  • Esophageal strictures preventing endoscope passage (except Schatzki's ring)
  • Female participants who have reached menarche by Day -1
  • Known HIV positive status
  • History of Zollinger-Ellison syndrome or other hypersecretory conditions
  • Prior gastric, duodenal, or esophageal surgery except simple ulcer oversew
  • Acute upper gastrointestinal bleeding within 4 weeks before endoscopy
  • Significant blood loss or transfusion within 90 days before first dose
  • History of alcohol abuse or illegal drug use within 12 months before first dose
  • Abnormal lab values indicating significant disease or condition
  • Immediate family or dependent relationship with study staff
  • Unlikely to comply with protocol or unsuitable for any reason
  • Participation in another clinical trial or use of investigational drugs within 30 days before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 33 locations

1

Childrens Center for Digestive Health Care, LLC

Mobile, Alabama, United States, 36604

Actively Recruiting

2

University of Utah/ Primary Childrens Hospital

San Francisco, California, United States, 94158

Actively Recruiting

3

Gastrointestinal Associates, PA

Centennial, Colorado, United States, 80112

Withdrawn

4

Envision Clinical Research, LLC

Miami, Florida, United States, 33155

Withdrawn

5

GI For Kids

Atlanta, Georgia, United States, 30342

Actively Recruiting

6

Strada Patient Care Center, Department of Pediatric Gastroenterology

Chicago, Illinois, United States, 60637

Withdrawn

7

Childrens Hospital of The Kings Daughters

Jackson, Mississippi, United States, 39232

Actively Recruiting

8

Maspons Pediatric Gastro

Manchester, New Hampshire, United States, 79902

Withdrawn

9

The University of Chicago

Cleveland, Ohio, United States, 44106

Actively Recruiting

10

Dartmouth-Hitchcock Manchester

Oklahoma City, Oklahoma, United States, 73104

Withdrawn

11

University of California San Francisco

Oklahoma City, Oklahoma, United States, 73112

Withdrawn

12

c/o Chelsea Campbell, RN

Knoxville, Tennessee, United States, 37922

Withdrawn

13

Vanderbilt University Medical Center,

Nashville, Tennessee, United States, 37212

Withdrawn

14

Oklahoma Pediatric Digestive Institute

El Paso, Texas, United States, 79902

Withdrawn

15

University Hospitals Cleveland Medical Center

Laredo, Texas, United States, 78041

Withdrawn

16

IMMUNOe Research Centers

Salt Lake City, Utah, United States, 84113

Withdrawn

17

National Research Centers

Norfolk, Virginia, United States, 23507

Actively Recruiting

18

Women and Children's Health Research Institute

Edmonton, Alberta, Canada, T6G 1C9

Actively Recruiting

19

London Health Sciences Centre Children's Hospital

London, Ontario, Canada, N6A 5W9

Actively Recruiting

20

Hospital Universitario San Ignacio

Bogotá, Colombia, 110231

Actively Recruiting

21

Fundacion Valle del Lili

Cali, Colombia, 760032

Actively Recruiting

22

Centro Medico Imbanaco de Cali S.A

Cali, Colombia, 760042

Actively Recruiting

23

Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Public Institution

Kaunas, LT, Lithuania, LT-50161

Withdrawn

24

Vilnius University Hospital Santaros Klinikos, Public Institution

Vilnius, LT, Lithuania, LT-08406

Withdrawn

25

InspirePharma S. de R.L. de C.V.

Monterrey, Nuevo León, Mexico, 64660

Withdrawn

26

Boca Clinical Trials Mexico S.C.

Querétaro, Putumayo, Mexico, 1120

Actively Recruiting

27

Clinical Research Institute S.C.

Tlalnepantla, State of Mexico, Mexico, 54055

Actively Recruiting

28

El Cielo Medical Center

Puebla City, Mexico, 72160

Actively Recruiting

29

SMIQ, S. DE R.L. DE C.V. Queretaro

Querétaro, Mexico, 76070

Actively Recruiting

30

Gabinet Lekarski Bartosz Korczowski

Rzeszów, PL, Poland, 35-302

Active, Not Recruiting

31

In Vivo Osrodek Badan Klinicznych

Bydgoszcz, Poland, 85-048

Active, Not Recruiting

32

Instytut "Pomnik - Centrum Zdrowia Dziecka", Oddzial Gastroenterologii, Hepatologii, Zaburzen odzywiania i Pediatrii

Warsaw, Poland, 04-730

Active, Not Recruiting

33

Uniwersytecki Szpital Kliniczny im.Jana Mikulicza-Radeckiego we Wroclawiu

Wroclaw, Poland, 50-369

Withdrawn

Loading map...

Research Team

T

Takeda Contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old | DecenTrialz